Integrating Complimentary and Alternative Medicine in Form of Active Hexose Co-Related Compound (AHCC) in the Management of Head & Neck Cancer Patients
Dillip Kumar Parida, Koji Wakame, Taisei Nomura
DOI: 10.4236/ijcm.2011.25097   PDF    HTML     7,006 Downloads   11,850 Views   Citations


Objectives: The Active Hexose Correlated Compound (AHCC), is produced from mushroom mycerium and rich in alpha glucans was administered to the cancer patients along with chemotherapy to see if it is having any beneficial effects on the final outcome in terms of reducing side effects of chemotherapy, maintaining the general condition and having effect on tumor control. Methods: Twenty five patients were administered AHCC along with conventional palliative chemotherapy regimen out of which sixteen patients received paclitaxel, and cisplatinum/carboplatin, nine patients received combination of cisplatim and 5-Flurouracil. All the patients were having advance stage (T3/T4) head and neck cancers. Thirteen patients were cancer of cheek, followed by cancer of tongue (4), oro-pharyngeal cancer (6) and cancer of naso-pharynx (2). Results: All the patients tolerated AHCC well with no added symptoms. Twenty patients reported that they are feeling stronger than before at the time of initiation of chemotherapy cycles. Almost all the patients reported to have better appetite after they started taking AHCC. Twelve patients who required blood transfusion before chemotherapy cycles, decrease in the rate of fall in hemoglobin was observed in these patients and only three patients required blood transfusion before subsequent chemotherapy cycles. In 22 patients definite reduction of chemotherapy side effects like nausea, vomiting, drop in total leucocytes count, loose motion/constipation etc. were observed, which reduced the hospital stay of these patients. Tumor regressed in 11 patients, 8 patients had stable disease and in rest of the patients, the disease progressed. Conclusions: AHCC up to 3 g is safe to administer and definitely helps cancer patients in reducing side effects of chemotherapeutic drugs, getting a sense of wellbeing and improved intake maintains general condition as well as prepare them to continue and tolerate further cycles in a better way.

Share and Cite:

D. Parida, K. Wakame and T. Nomura, "Integrating Complimentary and Alternative Medicine in Form of Active Hexose Co-Related Compound (AHCC) in the Management of Head & Neck Cancer Patients," International Journal of Clinical Medicine, Vol. 2 No. 5, 2011, pp. 588-592. doi: 10.4236/ijcm.2011.25097.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] National Cancer Registry P Publication 2007.
[2] P. Jha, B. Jacob, V. Gajalakshmi, P. C. Gupta, N. Dhingra, R. Kumar, D. N. Sinha, R. P. Dikshit, D. K. Parida, R. Kamadod, J. Boreham, R. Peto and RGI-CGHR Investigators, “A Nationally Representative Case-Control Study of Smoking and Death in India,” New England Journal of Medicine, Vol. 358, No. 11, 2008, pp. 1137-1147. doi:10.1056/NEJMsa0707719
[3] Y. Gao, D. Zhang, B. X. Sun, H. Fujii, K. Kosuna and Z. Yin, “Active Hexose Correlated Compound Enhances Tumor Surveillance through Regulating both Innate and Adaptive Immune Responses,” Cancer Immunology Immunotherapy, Vol. 55, No. 10, 2006, pp. 1258-1266. doi:10.1007/s00262-005-0111-9
[4] N. Terakawa, Y. Matsui, S. Satoi, et al., “Immunological Effect of Active Hexose Correlated Compound (AHCC) in Healthy Volunteers: A Double-Blind, Placebo-Controlled Study,” Nutrition and Cancer, Vol. 60, No. 5, 2008, pp. 643-651. doi:10.1080/01635580801993280
[5] S. Wasser and A. Weis, “Therapeutic Effects of Substances Occurring in Higher Basidiomycetes Mushrooms: A Modern Perspective,” Critical Reviews in Immunology, Vol. 19, No. 1, 1999, pp. 65-96.
[6] R. Burikhanov, K. Wakame, Y. Igarashi, S. Wang, S. Matsuzaki, “Suppressive Effect of Active Hexose Correlated Compound on Thymic Apoptosis Induced by Dexamethasone in the Rat,” Endocrine Research, Vol. 34, 2000, pp. 181-188.
[7] T. Nomura, et al., “Antiteratogenic Effects of Tumor Inhibitors, Caffeine, Antipain, and Retinoic Acid in Mice,” Cancer Research, Vol. 43, 1983, pp. 5156-5162.
[8] Y. Matsui, J. Uhara, S. Satoi, M. Kaibori, H. Yamada, H. Kitade, A. Imamura, S. Takai, Y. Kawaguchi, A. Kwon and Y. Kamiyama, “Improved Prognosis of Postoperative Hepatocellular Carcinoma Patients When Treated with Functional Foods: A Prospective Cohort Study,” Journal of Hepatology, Vol. 37, No. 1, 2002, pp. 78-86. doi:10.1016/S0168-8278(02)00091-0
[9] C. Suwanna, et al., “Prognostic Improvement of Patients with Advanced Liver Cancer after Active Hexose Correlated Compound (AHCC) Treatment,” Asian Pacific Journal of Allergy & Immunology, Vol. 24, No. 1, 2006, pp. 33-45.
[10] E. L. Spierings, H. Fujii, B. Sun and T. Walshe, “A Phase I Study of the Safety of the Nutritional Supplement, Active Hexose Correlated Compound (AHCC) in Healthy Volunteers,” Journal of Nutritional Science & Vitaminology, Vol. 53, No. 6, 2007, pp. 536-539. doi:10.3177/jnsv.53.536
[11] I. Hyodo, N. Amano and K. Eguchi, “Nationwide Survey on Complementary and Alternative Medicine in Cancer Patients in Japan,” Journal of Clinical Oncology, Vol. 23, No. 12, 2005, pp. 2645-2654. doi:10.1200/JCO.2005.04.126
[12] K. Matsushita, et al., “Combination Therapy of Active Hexose Correlated Compound (AHCC) Plus UFT Significantly Reduces the Metastasis of Rat Mammary Carcinoma,” Anti-Cancer Drugs, Vol. 9, 1998, pp. 343-350. doi:10.1097/00001813-199804000-00008
[13] A. Hirose, E. Sato, H. Fujii, S. Buxiang, H. Nishioka and O. I. Aruoma, “The Influence of Active Hexose Correlated Compound (AHCC) on Cisplatin-Evoked Chemotherapeutic and Side Effects in Tumor-Bearing Mice,” Toxicology and Applied Pharmacology, Vol. 222, No. 2, 2007, pp. 152-158. doi:10.1016/j.taap.2007.03.031
[14] C. Mach, H. Fujii, K. Wakame and J. Smith, “Evaluation of Active Hexose Correlated Compound Hepatic Metabolism and Potential for Drug Interactions with Chemotherapy Agents,” Journal of the Society for Integrative Oncology, Vol. 6, No. 3, 2008, pp. 105-109.
[15] K. Shigama, A. Nakaya, K. Wakame, H. Nishioka and H. Fujii, “Alleviating Effect of Active Hexose Correlated Compound (AHCC) for Anticancer Drug-Induced Side Effects in Non-Tumor-Bearing Mice,” Journal of Experimental Therapeutics and Oncology, Vol. 8, No. 1, 2009, pp. 43-51.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.